Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Oncology Letters
      • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Biomedical Reports
      • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • Information for Authors
    • Information for Reviewers
    • Information for Librarians
    • Information for Advertisers
    • Conferences
  • Language Editing
Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • For Authors
    • For Reviewers
    • For Librarians
    • For Advertisers
    • Conferences
  • Language Editing
Login Register Submit
  • This site uses cookies
  • You can change your cookie settings at any time by following the instructions in our Cookie Policy. To find out more, you may read our Privacy Policy.

    I agree
Search articles by DOI, keyword, author or affiliation
Search
Advanced Search
presentation
International Journal of Molecular Medicine
Join Editorial Board Propose a Special Issue
Print ISSN: 1107-3756 Online ISSN: 1791-244X
Journal Cover
January-2027 Volume 59 Issue 1

Full Size Image

Sign up for eToc alerts
Recommend to Library

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

Medicine International

An International Open Access Journal Devoted to General Medicine.

Journal Cover
January-2027 Volume 59 Issue 1

Full Size Image

Sign up for eToc alerts
Recommend to Library

  • Article
  • Citations
    • Cite This Article
    • Download Citation
    • Create Citation Alert
    • Remove Citation Alert
    • Cited By
  • Similar Articles
    • Related Articles (in Spandidos Publications)
    • Similar Articles (Google Scholar)
    • Similar Articles (PubMed)
  • Download PDF
  • Download XML
  • View XML

  • Supplementary Files
    • Supplementary_Data.pdf
Article Open Access

A novel role of NOX2 in enhancing HBV replication through ROS‑mediated autophagy activation

  • Authors:
    • Xiaoyu Sun
    • Lili Deng
    • Jun Yang
    • Lingbing Chen
    • Meimei Ren
    • Guowei He
    • Yi Zhang
    • Liang Cheng
    • Bo Wang
  • View Affiliations / Copyright

    Affiliations: Department of Laboratory Medicine, The Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, P.R. China
    Copyright: © Sun et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
  • Article Number: 7
    |
    Published online on: November 16, 2026
       https://doi.org/10.3892/ijmm.2026.6054
  • Expand metrics +
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Cited By (CrossRef): 0 citations Loading Articles...

This article is mentioned in:


Abstract

Hepatitis B virus (HBV) is a serious global public health issue. Mounting evidence suggests that NADPH oxidase 2 (NOX2) plays critical roles in various physiological and pathological processes. However, the underlying mechanisms by which NOX2 affects HBV infection remain to be elucidated. In the present study, the potential role of NOX2 in HBV replication was investigated in cell models. First, it was demonstrated that NOX2 is highly expressed in transiently and stably HBV‑infected cells. Second, by employing inhibitor, RNA interference technique and plasmid overexpression, it was revealed that NOX2 plays an essential role in promoting HBV replication. Furthermore, the underlying mechanism of how NOX2 affects HBV replication was illustrated. It was found that NOX2‑mediated ROS induce an increase of intracellular autophagy levels, which result in facilitating HBV replication. These results suggested a previously unrecognized role of NOX2 in HBV replication. Taken together, NOX2 may serve as a novel target for developing treatment strategies against HBV‑related disorders.

Introduction

The persistent global burden of hepatitis B virus (HBV) infection, exacerbated by pandemic spread and emerging antiviral resistance, remains a critical public health challenge. According to the World Health Organization reports, ~2 billion individuals globally are infected with HBV, with nearly 350 million individuals progressing to chronic hepatitis B (CHB). Furthermore, HBV-related complications, including liver cirrhosis and hepatocellular carcinoma (HCC), cause more than 1 million individual deaths each year (1-3). Current therapeutic strategies are reported to significant clinical limitations including adverse effects, high costs, and incomplete efficacy (4). Nucleos(t)ide analogues are common drugs for HBV infection, since they are able to suppress viral replication through inhibiting polymerase. However, they fail to achieve complete virological cure due to their inability to eliminate covalently closed circular DNA reservoirs (5). Therefore, it is important to elucidate the precise molecular mechanisms involving viral persistence, disease progression, and host-virus interactions for the development of curative therapeutic strategies targeting viral eradication.

Over the years, increasing evidence suggests that reactive oxygen species (ROS) play dual roles in both physiological and pathological processes. The role of oxidative stress in HBV-associated pathologies has recently attracted significant attention. One proposed mechanism indicates that HBV-induced mitochondrial ROS accumulation suppresses SOCS3 expression via Snail-mediated epigenetic silencing, leading to sustained activation of the IL-6/STAT3 pathway, which promotes hepatocarcinogenesis (6). Conversely, findings by Yu et al (7) revealed that chronic HBV infection can attenuate lipopolysaccharide-induced NLRP3 inflammasome activation and IL-1β production via HBeAg-mediated suppression of ROS and NF-κB signaling. These studies collectively highlight the pivotal and complex role of ROS in modulating host defense and inflammatory responses during viral infections.

The NADPH oxidase (NOX) family, comprising seven isoforms (NOX1-5 and DUOX1-2), represents one of the primary cellular sources of ROS (8). Among these isoforms, NOX2, encoded by the CYBB gene, is predominantly expressed in neutrophils, monocytes, vascular endothelial cells and cardiomyocytes (8,9). Functionally, phagocyte NOX2 is essential for antimicrobial defense and inflammatory responses, while non-phagocytic role of NOX2 is involved in intracellular signaling and gene regulation (10,11). Emerging evidence underscores the critical role of NOX2 in various pathological conditions. For example, chronic granulomatous disease is a hereditary disorder caused by NOX2 deficiency characterized by impaired reactive oxygen intermediate production in phagocytes, leading to elevated circulating type I interferons and autoantibodies, which in turn increase susceptibility to bacterial and fungal infections (12,13). Similarly, NOX2 deficiency has been shown to exacerbate the pathogenesis of systemic lupus erythematosus in both clinical and murine models (14). Importantly, NOX2 plays a significant role in viral infections. For instance, Youn et al (15) demonstrated that the HIV-1 Tat protein enhances NOX2-dependent ROS generation, which subsequently activates the MAPK/NF-κB/AP-1 pathway to upregulate HDAC6 and amplify pro-inflammatory cytokine expression. In addition, studies revealed that HIV infection induces platelet activation via NOX2-mediated oxidative stress, suggesting that anti-platelet therapies targeting NOX2 (for example, HART) could help mitigate cardiovascular complications in patients with HIV (16). Notably, elevated serum NOX2 levels were observed in patients with CHB, cirrhosis and HCC, which correlated positively with disease progression (17). These results indicated that NOX2 participated in pathogenesis of HBV infection, while the underlying mechanism remains unclear and needs to be further addressed.

In the present study, the functional interplay between NOX2 and HBV infection was investigated through pharmacological inhibition (chemical inhibitors), genetic knockdown (RNA interference), and overexpression approaches. The present findings aim to elucidate the pathogenic mechanisms underlying HBV infection and its associated complications, while potentially offering novel insights for clinical diagnosis and prognostic evaluation.

Materials and methods

Study subjects

From March 2023 to May 2024, individuals with either positive or negative HBV status were recruited from the Second Affiliated Hospital of Chongqing Medical University, following the collection of written informed consent. The serum samples obtained included 105 cases of CHB and 98 samples from healthy donors. The healthy controls tested negative for HBV, HCV and HIV. Diagnosis of CHB followed the 2015 version of the guidelines for the prevention and treatment of CHB (18), and enrolled patients had not received antiviral therapy for at least six months prior to participation. Imaging methods such as magnetic resonance imaging and computerized tomography were also employed to help differentiate CHB from other liver diseases. Available demographic and clinical characteristics, including age, sex, liver-function indicators, HBeAg status, and serum HBV DNA levels, are summarized in Table I. The study protocol received approval from the ethics committee of the Second Affiliated Hospital of Chongqing Medical University on January 2023 under approval no. 2025534 and was conducted in line with the Declaration of Helsinki. Peripheral blood samples were collected, left at room temperature for 30 min to allow clotting, and then centrifuged at 1,000 × g for 10 min. The resulting serum supernatant was immediately aliquoted and stored at −80°C until analysis.

Table I

Clinical characteristics of subjects in the present study.

Table I

Clinical characteristics of subjects in the present study.

Clinical characteristicsHealthy individualsCHB
Number of subjects98105
Age, years (range)23-6719-65
Age, years (mean)40.239.1
Sex (male: female)50:4851:54
HBeAg(+) CHB-49.52%
ALT, U/l (mean ± SD)23.47±13.46120.56±245.25
AST, U/ (mean ± SD)22.47±8.2681.06±120.35
HBV DNA, copies/ml (mean ± SD)- 9,861,635.81±22,344,824.14
TAC, mmol Trolox Eq./l (mean ± SD)2.65±0.891.63±0.47
TOA, μmol/l H2O2 Eq./l (mean ± SD)30.08±6.6849.12±19.99
NOX2, pg/ml (mean ± SD)922.72±479.21 2,948.38±1,094.09

[i] CHB, chronic hepatitis B; TAC, total antioxidant capacity; TOA, total oxidant activity; ALT, alanine aminotransferase; AST, aspartate aminotransferase; HBV, hepatitis B virus; NOX2, NADPH oxidase 2.

Reagents

Apocynin, rapamycin, 3-methyladenine (3-MA), GSK2795039, N-acetyl-L-cysteine (NAC) and Trolox were purchased from MedChemExpress. NAC is a thiol-containing antioxidant that primarily supports intracellular glutathione synthesis and redox homeostasis, whereas Trolox is a water-soluble vitamin E analogue that scavenges free radicals and inhibits oxidative chain reactions. Cells were treated with NAC (5 mM) or Trolox (200 μM) in the current setting. ROS assay kit was purchased from Beyotime Institute of Biotechnology. Oligonucleotides used in PCR were synthesized by Invitrogen; Thermo Fisher Scientific, Inc. RNA interference oligonucleotides were synthesized by Shanghai GenePharma Co., Ltd. with the following oligonucleotide sequences: NOX2 small interfering RNA (siRNA) sense, 5'-GAAGACAACUGGACAGGAAUU-3' and antisense, 5'-UUCCUGUCCAGUUGUCUUCUU-3'; and negative control siRNA sense, 5'-UUCUCCGA-ACGUGUCACGUTT-3' and antisense, 5'-ACGUGACACGUUCGGAGAATT-3'.

Plasmid and antibody

The empty plasmid (vector), plasmid contain 1.1- or 1.3-fold HBV genome fragment (HBV1.1, HBV1.3) were constructed in the authors' laboratory. The plasmid of NOX2 and control plasmid were obtained from GeneCopoeia. The mammalian expression vectors HyPer-cyto (Evrogen) were commercially obtained. The primary antibodies were as follows: rabbit anti-NOX2 (1:1,000; cat. no. Ab310337; Abcam), rabbit anti-LC3I/II (1:1,000; cat. no. ab62721; Abcam), mouse anti-p62 (1:1,000; cat. no. 88588; Cell Signaling Technologies, Inc.), rabbit anti-HBc (hepatitis B core protein) (1:500; cat. no. B0586; Dako; Agilent Technologies, Inc.) and mouse anti-β-actin (1:1,000; cat. no. 12262; Cell Signaling Technologies, Inc.). HRP-conjugated Goat Anti-Rabbit IgG(H+L) (Hepatitis B core protein) (1:1,000; cat. no. 11904; Proteintech Group, Inc.), HRP-conjugated Goat Anti-Mouse IgG(H+L) (1:1,000; cat. no. 16256; Proteintech Group, Inc.).

Cell culture

The human liver cancer-derived cell line HepG2 (cat. no. SCC-110211; Beijing Solarbio Science & Technology Co., Ltd.;) was maintained in minimum essential medium (Hyclone; Cytiva) supplemented with 10% heat-inactivated fetal bovine serum (FBS) (Gibco; Thermo Fisher Scientific, Inc.), 100 U/ml penicillin and 100 U/ml streptomycin. HepG2.2.15 cells, an HBV-producing derivative of the human liver cancer-derived HepG2 cell line (cat. no. SNL-559; Wuhan Sunncell Biotech Co., Ltd.), were maintained in Dulbecco's modified Eagle's medium (DMEM) (Hyclone; Cytiva) supplemented with 10% FBS, 100 U/ml penicillin, 100 U/ml streptomycin and 400 μg/ml G418 (MilliporeSigma). Both cell lines were cultured at 37°C in a humidified atmosphere containing 5% CO2.

Transfections

HepG2 cells were transfected with empty vector, HBV1.1 and HBV1.3 plasmids using lipofectamine 2000 (Invitrogen; Thermo Fisher Scientific, Inc.). HepG2 cells or HepG2.2.15 cells were transfected with NOX2-specific siRNA or negative control siRNA using siRNA-mate transfection reagent (GenePharm, Inc.). Plasmid DNA (2.5 μg per well) or siRNA (30, 60, 120, 180 pM) was introduced into cells according to manufactures' protocols. Transfections were performed at 37°C in a humidified atmosphere containing 5% CO2. The culture medium was replaced with fresh antibiotic-free medium 4-6 h after plasmid transfection. The cells were collected after indicated time for the subsequent experiment.

Measurement of sNOX2-dp by ELISA

Soluble NOX2-derived peptide (sNOX2-dp), a circulating marker associated with NOX2 activation, has been investigated as an indicator of oxidative stress in various pathological conditions (8). In a previous study by the authors, serum sNOX2-dp concentrations were significantly elevated in patients with HBV-associated liver diseases and correlated with disease progression (17). In brief, microplate wells pre-coated with an anti-NOX2/gp91phox antibody (1:1,500; cat. no. ab300696; Abcam) received 100 μl of either serum specimens or standard solutions, followed by incubation for 2 h at room temperature under shaking conditions. After three washes, 100 μl of diluted HRP-conjugated detection antibody (1:100,000; cat. no. ab6759; Abcam) was added to each well, and the plate was incubated for 1 h at room temperature with gentle agitation. The wells were then aspirated and washed three more times. Subsequently, 100 μl of enzyme substrate solution was dispensed into all wells and left to react for 20 min at room temperature. The reaction was halted by adding 50 μl of 1 mol/l H2SO4 as a stop solution. Absorbance readings were received at 450 nm using a Multiskan™ FC microplate reader (Thermo Fisher Scientific, Inc.).

Measurement of total antioxidant capacity (TAC) and total oxidant activity (TOA)

Serum TAC and TOA were determined using automated colorimetric assays, as previously described (19), with appropriate modifications. TAC values were calibrated against Trolox standards and expressed as mmol Trolox equivalents/l. TOA values were calibrated against hydrogen peroxide standards and expressed as μmol H2O2 equivalents/l. Measurements were performed using spectrophotometer, according to the established assay protocol.

Western blotting

Western blot analysis was applied to detected levels of NOX2, HBc, p62, LC3 and β-actin. Briefly, the treated cells were collected and washed with ice-cold PBS, then lysed in a buffer containing 20 mM Hepes (pH 7.4), 100 mM NaCl, 5 mM EDTA (pH 7.4) 1 mM Na3VO4, 30 mM NaF, 5% glycerol, 0.1% SDS, 1% Triton X-100, 10 mM p-nitro-phenyl-phosphate, 1 mM glycerophosphate, supplemented with complete protease inhibitors (Selleck Chemicals). Next, proteins were harvested after centrifugation at 16,000 × g and 4°C. Total protein concentrations were determined using the The Pierce BCA Protein Assay Kit according (Thermo Fisher Scientific, Inc.) to the manufacturer's instructions. Equal amounts of total protein (20 μg per lane) were separated in 12% or 15% SDS-PAGE and electro-transferred to the PVDF membranes, which were blocked at room temperature with 5% BSA (Proteintech Group, Inc.) for 2 h, and subsequently incubated with indicated antibodies overnight at 4°C, followed by incubation with secondary antibodies at room temperature for 2 h. The immunoreactive protein bands were visualized using enhanced chemiluminescence and recorded using a Bio-Rad imaging system. Densitometric analysis was performed using ImageJ software (version 1.54g; National Institutes of Health). The relative expression levels of NOX2, HBc and p62 were calculated by normalizing the integrated optical density of each target protein band to that of β-actin in the corresponding sample. LC3-I and LC3-II bands were quantified separately, and the LC3-II/LC3-I ratio was calculated to assess changes in autophagy-associated protein expression. All western blot experiments were performed in three independent biological replicates (n=3). Quantitative results were expressed as the mean ± standard deviation (SD), and statistical comparisons were performed using appropriate statistical tests.

Reverse transcription-quantitative PCR (RT-qPCR) analysis

Total RNA was isolated from treated cells using a TRIzol reagent kit (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's instructions. cDNA was synthesized using the PrimeScript™ II 1st Stand cDNA Synthesis Kit (Takara Bio, Inc.) according to the manufacturer's instructions. PCR amplification of cDNA aliquots was performed with the following primer sequences: NOX2 sense, 5'-TGTTCAGCTATGAGGTGGTGA-3' and antisense, 5'-TCAGATTGGTGGCGTTATTG-3'; HBV 3.5kb sense, 5'-GCCTTAGAGTCTCCTGAGCA-3' and antisense, 5'-GAGGGAGTTCTTCTTCTAGG-3'; and β-actin sense, 5'-ACAATGAGCTGCTGGTGGCT-3' and antisense, 5'-GATGGGCACAGTGTGGGTGA-3'; Each 10 μl of reaction contained 5 μl of 5X SYBR Green Supermix, 0.5 μl of target gene primer mix, and 100 ng of a cDNA template. The PCR reaction was set up as follows: Initial denaturation step at 95°C for 15 min, followed by 40 cycles of 30 sec at 95°C, at 60°C for 30 sec and at 72°C for 30 sec. Reactions were performed in triplicate using an CFX Connect™ Real-Time PCR Detection System (Bio-Rad Laboratories, Inc.) and normalized to β-actin mRNA level using the 2−ΔΔCq method (20).

Immunofluorescence (IF)

The cells were plated and cultured onto cleaned-up cover slips and were washed with PBS and fixed in 4% paraformaldehyde for 15 min at room temperature, then permeabilized with 0.2% Triton X-100 for 10 min and blocked with goat serum (Proteintech Group, Inc.) for 1 h in 37°C drying oven. Then, the cells were incubated with diluted antibodies (1:200) more than 1 h, followed by either goat or anti-rabbit secondary antibody (1:500), after each step of the aforementioned process, washed with PBS (5 min × 3 times). To visualize nuclei, cells were stained with 10 μg/ml DAPI (21). The fluorescent images were then observed and analyzed using a multilaser confocal microscope. 2',7'-dichlorofluorescein (DCF-DA) is oxidized by intracellular ROS and forms green-fluorescent DCF. The images shown are representative of three independent experiments.

Measurement of intracellular ROS

DCF-DA, which is converted by intracellular ROS into green-fluorescent DCF, was used to evaluate intracellular ROS level. The cells were harvested after treatment for 48 h in a 1.5-ml centrifuge tube, washed twice with pre-chilled PBS, and then treated with 500 μl DMEM supplemented with 20 μmol/l DCF-DA for 30 min in the dark. Finally, the cells were washed twice with PBS and resuspended in 500 μl PBS. The fluorescence intensity of DCF, reflecting the concentration of ROS, was measured by BD FACS Canto™ II flow cytometer (BD Biosciences). Cytosolic H2O2-associated redox changes were monitored using the genetically encoded HyPer-cyto fluorescent sensor. HyPer exhibits two excitation maxima at ~420 and 500 nm, and its excitation spectrum changes following oxidation. The fluorescence excitation ratio (500/420 nm) was used as a ratio-metric indicator of cytosolic sensor oxidation. HepG2 cells expressing the HBV1.3 construct were analyzed in the presence or absence of antioxidant treatment.

Statistical analyses

Statistical analyses were performed using SPSS 20.0 statistical software (IBM Corp.). Data are presented as the mean ± standard deviation unless otherwise specified. The number of independent biological replicates is indicated in the corresponding figure legends. For comparisons between two independent groups, an appropriate two-sided statistical test was applied. Comparisons involving three or more groups were analyzed using one-way analysis of variance (ANOVA), followed by Dunnett's post-hoc test for comparisons against a designated control group. Correlation analyses were performed using Pearson's or Spearman's correlation coefficients, depending on the distribution and characteristics of the variables. Statistically significant difference was defined as P<0.05.

Results

HBV infection upregulates NOX2 expression in liver cancer cell models

Previously, strong evidence was provided that soluble NOX2-derived peptide (sNOX2-dp) is a critical indicator of pathogenesis of progression of HBV-relation complications (17). In the present study, these findings were confirmed and extended by showing that the level of sNOX2-dp is significantly higher in patients with CHB than in healthy individuals (Fig. 1A). In addition, it was demonstrated that a clearly positive correlation between sNOX2-dp and HBV DNA levels in patients with CHB (r=0.4674, P<0.0001, Fig. 1B). To determine whether HBV modulates NOX2 expression, both protein and mRNA levels of NOX2 in HepG2 and HepG2.2.15 cell lines were analyzed using western blotting and RT-qPCR. Notably, HepG2.2.15 cells, which stably replicate HBV, exhibited significantly higher NOX2 expression compared with parental HepG2 cells, as confirmed by densitometric quantification (Fig. 1C and E). To further validate this finding, transient HBV-infected cell models were established by transfecting HepG2 cells with HBV1.1 or HBV1.3 plasmids. Consistent with initial observations, both HepG2-HBV1.1 and HepG2-HBV1.3 cells demonstrated significantly elevated NOX2 levels relative to vector-transfected controls (Fig. 1D and F). Complementing these results, IF staining revealed a pronounced increase in NOX2 fluorescence intensity in both HepG2.2.15 and HepG2-HBV1.1/1.3 cells compared with their respective control groups (Fig. 1G and H). These data collectively indicate that HBV infection robustly upregulates NOX2 expression in hepatic cell models.

HBV infection increases NOX2
expression in hepatic cell models. (A) Serum soluble NOX2-derived
peptide (sNOX2-dp) concentrations were measured in healthy
individuals and patients with CHB. Patients with CHB exhibited
significantly elevated circulating sNOX2-dp levels compared with
healthy controls (P<0.01). (B) Correlation analysis between
serum sNOX2-dp concentrations and HBV DNA levels in patients with
CHB. A significant positive correlation was observed between NOX2
activity and viral load (r=0.4674, P<0.0001). (C) Representative
western blot images and corresponding densitometric quantification
of NOX2 protein expression in parental HepG2 and HBV-replicating
HepG2.2.15 cells. (D) Representative western blot analysis and
densitometric quantification of NOX2 protein expression in HepG2
cells transfected with empty vector, HBV genotype 1.1, or HBV
genotype 1.3 plasmids. (E) RT-qPCR analysis of NOX2 mRNA expression
in HepG2 and HepG2.2.15 cells. NOX2 transcript levels were
significantly increased in HepG2.2.15 cells compared with HepG2
cells (P<0.01). (F) RT-qPCR analysis of NOX2 mRNA expression in
HepG2 cells transfected with HBV genotype 1.1 or genotype 1.3
plasmids. HBV expression significantly upregulated NOX2 mRNA levels
compared with vector-transfected controls (P<0.01). (G)
Representative IF staining of NOX2 (green) in HepG2 and HepG2.2.15
cells. Nuclei were counterstained with DAPI (blue). Merged images
demonstrate enhanced NOX2 fluorescence intensity in HBV-producing
HepG2.2.15 cells. (H) Representative IF staining of NOX2 (green) in
HepG2 cells transfected with empty vector, HBV genotype 1.1, or HBV
genotype 1.3 plasmids. DAPI (blue) was used for nuclear staining.
HBV expression markedly increased NOX2 immunoreactivity compared
with vector controls. Scale bar, 50 μm. Data are presented
as individual values with the mean ± SD of three independent
experiments. HBV, hepatitis B virus; NOX2, NADPH oxidase 2; CHB,
chronic hepatitis B; RT-qPCR, reverse transcription-quantitative
PCR; IF, immunofluorescence.

Figure 1

HBV infection increases NOX2 expression in hepatic cell models. (A) Serum soluble NOX2-derived peptide (sNOX2-dp) concentrations were measured in healthy individuals and patients with CHB. Patients with CHB exhibited significantly elevated circulating sNOX2-dp levels compared with healthy controls (P<0.01). (B) Correlation analysis between serum sNOX2-dp concentrations and HBV DNA levels in patients with CHB. A significant positive correlation was observed between NOX2 activity and viral load (r=0.4674, P<0.0001). (C) Representative western blot images and corresponding densitometric quantification of NOX2 protein expression in parental HepG2 and HBV-replicating HepG2.2.15 cells. (D) Representative western blot analysis and densitometric quantification of NOX2 protein expression in HepG2 cells transfected with empty vector, HBV genotype 1.1, or HBV genotype 1.3 plasmids. (E) RT-qPCR analysis of NOX2 mRNA expression in HepG2 and HepG2.2.15 cells. NOX2 transcript levels were significantly increased in HepG2.2.15 cells compared with HepG2 cells (P<0.01). (F) RT-qPCR analysis of NOX2 mRNA expression in HepG2 cells transfected with HBV genotype 1.1 or genotype 1.3 plasmids. HBV expression significantly upregulated NOX2 mRNA levels compared with vector-transfected controls (P<0.01). (G) Representative IF staining of NOX2 (green) in HepG2 and HepG2.2.15 cells. Nuclei were counterstained with DAPI (blue). Merged images demonstrate enhanced NOX2 fluorescence intensity in HBV-producing HepG2.2.15 cells. (H) Representative IF staining of NOX2 (green) in HepG2 cells transfected with empty vector, HBV genotype 1.1, or HBV genotype 1.3 plasmids. DAPI (blue) was used for nuclear staining. HBV expression markedly increased NOX2 immunoreactivity compared with vector controls. Scale bar, 50 μm. Data are presented as individual values with the mean ± SD of three independent experiments. HBV, hepatitis B virus; NOX2, NADPH oxidase 2; CHB, chronic hepatitis B; RT-qPCR, reverse transcription-quantitative PCR; IF, immunofluorescence.

Pharmacological inhibition of NOX2 suppresses HBV replication

The present study was motivated by the observation of elevated NOX2 levels in HBV-infected hepatic cells, prompting us to investigate whether NOX2 upregulation influences HBV replication. To address this, apocynin was employed, a well-characterized pharmacological inhibitor of NOX2 enzymatic activity, which is widely used in experimental systems due to its efficacy and convenience. Initial experiments using HepG2.2.15 cells treated with different concentrations of apocynin demonstrated a progressive, dose-dependent reduction in HBV core protein (HBc) (Fig. 2A). Densitometric quantification demonstrated that even the lowest concentration of apocynin (1 μM) significantly decreased HBc expression, whereas higher concentrations (10-100 μM) produced more pronounced inhibitory effects (all P<0.01). Notably, the strong inhibitory effect was observed at 100 μM. To determine the optimal inhibitory time point, a time-course response in HepG2.2.15 cells was next evaluated using apocynin at 100 μM. The present findings indicated a significant reduction in both HBc and viral mRNA levels compared with untreated controls (Fig. 2B and C). In order to exclude cell model specificity, HepG2 transfected with HBV 1.3 plasmid was also employed to investigate the role of NOX2 in HBV infection. In the present study, evidence indicated that inhibiting the NOX2 enzymatic activity by apocynin could deter HBV replication in HepG2-HBV 1.3 cell models (Fig. 2D-F). Previous studies have demonstrated that apocynin can suppress NADPH oxidase activation by interfering with the assembly of cytosolic oxidase components, including p47phox and p67phox (22). Nevertheless, its pharmacological effects are context-dependent, and apocynin may also exert antioxidant activity independently of direct NOX2 inhibition (23). To further investigate the potential involvement of NOX2 in HBV replication-associated processes, the effects of GSK2795039 treatment on HBc abundance were examined in both transiently HBV-expressing HepG2-HBV1.3 cells and stably HBV-replicating HepG2.2.15 cells. GSK2795039, a pharmacological inhibitor of NOX2, was administered at a concentration of 25 μM, and intracellular HBc protein expression was subsequently evaluated by western blot analysis. As shown in Fig. S1A and B, treatment with GSK2795039 significantly decreased HBc protein abundance in HepG2-HBV1.3 cells and HepG2.2.15 cells compared with untreated controls (P<0.01). Densitometric quantification confirmed a significant decline in HBc expression following GSK2795039 exposure, suggesting that the compound inhibits HBc accumulation in HBV-expressing hepatocytes.

Inhibition of NOX2 activity by
apocynin suppresses HBV replication. (A) Representative western
blot images and corresponding densitometric quantification of HBc
expression in HepG2.2.15 cells treated with increasing
concentrations of apocynin (1, 10, 50, and 100 μM). (B)
Representative western blot analysis and densitometric
quantification of HBc protein expression in HepG2.2.15 cells
treated with 100 μM apocynin for 24, 48, or 72 h. (C)
RT-qPCR analysis of HBV 3.5-kb RNA expression in HepG2.2.15 cells
following treatment with 100 μM apocynin for the indicated
durations. (D) Representative western blot images and densitometric
analysis of HBc protein expression in HepG2 cells transfected with
the HBV 1.3 plasmid (HepG2-HBV1.3) and subsequently treated with
increasing concentrations of apocynin (1-100 μM). (E)
Representative western blot analysis and corresponding
densitometric quantification of HBc protein expression in
HepG2-HBV1.3 cells following exposure to 100 μM apocynin for
24, 48, or 72 h. (F) Relative expression of HBV 3.5-kb RNA in
HepG2-HBV1.3 cells treated with 100 μM apocynin for the
indicated durations, as determined by RT-qPCR. β-actin served as
the internal loading control for Western blot analysis. Protein
band intensities were quantified by densitometry and normalized to
β-actin. Data are presented as the mean ± SD of three independent
experiments. **P<0.01 compared with the corresponding
control group in panels A, B, D, and E; exact significance levels
for panels C and F are indicated above the comparison brackets
(P<0.05 or P<0.01). NOX2, NADPH oxidase 2; HBV, hepatitis B
virus; HBc, HBV core protein; RT-qPCR, reverse
transcription-quantitative PCR; NS, not significant.

Figure 2

Inhibition of NOX2 activity by apocynin suppresses HBV replication. (A) Representative western blot images and corresponding densitometric quantification of HBc expression in HepG2.2.15 cells treated with increasing concentrations of apocynin (1, 10, 50, and 100 μM). (B) Representative western blot analysis and densitometric quantification of HBc protein expression in HepG2.2.15 cells treated with 100 μM apocynin for 24, 48, or 72 h. (C) RT-qPCR analysis of HBV 3.5-kb RNA expression in HepG2.2.15 cells following treatment with 100 μM apocynin for the indicated durations. (D) Representative western blot images and densitometric analysis of HBc protein expression in HepG2 cells transfected with the HBV 1.3 plasmid (HepG2-HBV1.3) and subsequently treated with increasing concentrations of apocynin (1-100 μM). (E) Representative western blot analysis and corresponding densitometric quantification of HBc protein expression in HepG2-HBV1.3 cells following exposure to 100 μM apocynin for 24, 48, or 72 h. (F) Relative expression of HBV 3.5-kb RNA in HepG2-HBV1.3 cells treated with 100 μM apocynin for the indicated durations, as determined by RT-qPCR. β-actin served as the internal loading control for Western blot analysis. Protein band intensities were quantified by densitometry and normalized to β-actin. Data are presented as the mean ± SD of three independent experiments. **P<0.01 compared with the corresponding control group in panels A, B, D, and E; exact significance levels for panels C and F are indicated above the comparison brackets (P<0.05 or P<0.01). NOX2, NADPH oxidase 2; HBV, hepatitis B virus; HBc, HBV core protein; RT-qPCR, reverse transcription-quantitative PCR; NS, not significant.

Modulation of NOX2 expression affects HBV replication

To further understanding of the roles of NOX2 in HBV infection, NOX2 siRNA was employed to knockdown the expression of NOX2 in HBV infected cells. As shown in Fig. 3A, it was found that the expression NOX2 was downregulated by siNOX2 in dose-dependent manner, and that the level of HBc protein was also decreased by the suppressive expression of NOX2. Densitometric analysis confirmed significant decreases in NOX2 protein expression at concentrations of 60-180 pM, whereas the reduction at 30 pM was not statistically significant (Fig. 3A). In this context, it should be mentioned that 180 pM can significantly inhibit NOX2 level, and that this concentration was employed in subsequent experiments. Consistent with the positive effect of NOX2 on HBV replication, western blotting was applied to detect NOX2 and HBc levels at different time points after transfection with siNOX2. The blotting data also revealed that NOX2 levels were evidently reduced in HepG2.2.15 at 48 h post infection (hpi), 72 and 96 hpi, and that the levels of HBc in cells transfected with the siNOX2 was significantly lower than that of the negative-control group at 72 and 96 hpi (Fig. 3B). Furthermore, the RT-qPCR results in HepG2.2.15 cells revealed that siNOX2 significantly decreased the NOX2 RNA levels and HBV 3.5kb RNA levels (Fig. 3C and D). In addition, to validate these findings in an independent HBV-expression system, analogous NOX2 knockdown experiments were performed in HepG2-HBV 1.3 cell model. Western blot analysis demonstrated that transfection with increasing concentrations of siNOX2 (30-180 pM) progressively decreased NOX2 protein abundance (Fig. 3E). Significant suppression of NOX2 expression was observed at all tested concentrations, with the greatest reduction occurring at 180 pM. Correspondingly, HBc protein expression exhibited a concentration-dependent decrease, although statistically significant reductions were primarily detected at 120 and 180 pM. The temporal effects of NOX2 knockdown in HepG2-HBV1.3 cells were subsequently examined using 180 pM siNOX2. As demonstrated in Fig. 3F, NOX2 protein expression was significantly reduced at 48, 72, and 96 h compared with the corresponding negative controls. By contrast, HBc protein expression was not significantly affected at 48 h (P>0.05) but was significantly decreased at 72 h (P<0.05) and 96 h (P<0.001). Furthermore, RT-qPCR analysis confirmed that siNOX2 transfection significantly decreased NOX2 mRNA expression at all examined time points in HepG2-HBV1.3 cells (Fig. 3G). Analysis of HBV 3.5-kb RNA expression revealed a progressive reduction following NOX2 knockdown, with statistically significant decreases observed at 48 h (P<0.05), 72 h (P<0.01) and 96 h (P<0.01; Fig. 3H).

Silencing of NOX2 inhibits HBV
replication. (A) Representative western blot images and
corresponding densitometric quantification of NOX2 and HBc
expression in HepG2.2.15 cells transfected with increasing
concentrations of NOX2-specific siRNA (siNOX2; 30, 60, 120 and 180
pM). (B) Representative western blot analysis and densitometric
quantification of NOX2 and HBc protein expression in HepG2.2.15
cells following siNOX2 transfection for 48, 72, or 96 h, compared
with the corresponding NC groups. (C and D) RT-qPCR analysis of
NOX2 mRNA (C) and HBV 3.5-kb RNA (D) expression in HepG2.2.15 cells
at 48, 72, and 96 h following siNOX2 transfection. (E)
Representative western blot images and densitometric quantification
of NOX2 and HBc protein expression in HepG2 cells transfected with
the HBV 1.3 plasmid (HepG2-HBV1.3) and subsequently treated with
increasing concentrations of siNOX2 (30-180 pM). (F) Representative
western blot analysis and corresponding densitometric
quantification of NOX2 and HBc protein expression in HepG2-HBV1.3
cells transfected with 180 pM siNOX2 for 48, 72, or 96 h. (G and H)
Relative expression of NOX2 mRNA (G) and HBV 3.5-kb RNA (H) in
HepG2-HBV1.3 cells following siNOX2 transfection for the indicated
durations, as determined by RT-qPCR. β-actin served as the internal
loading control for western blot analysis, and protein band
intensities were quantified by densitometry and normalized to
β-actin. Data are presented as the mean ± SD of three independent
experiments. Statistical significance was determined relative to
the corresponding negative control groups, as indicated in each
panel: *P<0.05, **P<0.01 and
***P<0.001. NOX2, NADPH oxidase 2; HBV, hepatitis B
virus; HBc, HBV core protein; si-, small interfering; NC, negative
control; RT-qPCR, reverse transcription-quantitative PCR; NS, not
significant.

Figure 3

Silencing of NOX2 inhibits HBV replication. (A) Representative western blot images and corresponding densitometric quantification of NOX2 and HBc expression in HepG2.2.15 cells transfected with increasing concentrations of NOX2-specific siRNA (siNOX2; 30, 60, 120 and 180 pM). (B) Representative western blot analysis and densitometric quantification of NOX2 and HBc protein expression in HepG2.2.15 cells following siNOX2 transfection for 48, 72, or 96 h, compared with the corresponding NC groups. (C and D) RT-qPCR analysis of NOX2 mRNA (C) and HBV 3.5-kb RNA (D) expression in HepG2.2.15 cells at 48, 72, and 96 h following siNOX2 transfection. (E) Representative western blot images and densitometric quantification of NOX2 and HBc protein expression in HepG2 cells transfected with the HBV 1.3 plasmid (HepG2-HBV1.3) and subsequently treated with increasing concentrations of siNOX2 (30-180 pM). (F) Representative western blot analysis and corresponding densitometric quantification of NOX2 and HBc protein expression in HepG2-HBV1.3 cells transfected with 180 pM siNOX2 for 48, 72, or 96 h. (G and H) Relative expression of NOX2 mRNA (G) and HBV 3.5-kb RNA (H) in HepG2-HBV1.3 cells following siNOX2 transfection for the indicated durations, as determined by RT-qPCR. β-actin served as the internal loading control for western blot analysis, and protein band intensities were quantified by densitometry and normalized to β-actin. Data are presented as the mean ± SD of three independent experiments. Statistical significance was determined relative to the corresponding negative control groups, as indicated in each panel: *P<0.05, **P<0.01 and ***P<0.001. NOX2, NADPH oxidase 2; HBV, hepatitis B virus; HBc, HBV core protein; si-, small interfering; NC, negative control; RT-qPCR, reverse transcription-quantitative PCR; NS, not significant.

To further establish the functional involvement of NOX2 in HBV replication-associated processes, it was investigated whether ectopic overexpression of NOX2 could enhance HBV gene expression in both stably HBV-replicating HepG2.2.15 cells and transiently HBV-expressing HepG2 cells. As revealed in Fig. 4A, ectopic expression of NOX2 significantly increased intracellular NOX2 protein abundance compared with the negative control group (P<0.01), confirming successful NOX2 overexpression. Notably, this increase was accompanied by a significant elevation in HBc protein abundance (P<0.01). Densitometric analysis further demonstrated that NOX2 overexpression enhanced both NOX2 and HBc protein levels, suggesting that increased NOX2 abundance favors HBc accumulation in hepatocytes harboring replicating HBV genomes. Importantly, HBV 3.5-kb RNA abundance was also significantly elevated following NOX2 overexpression (P<0.01, Fig. 4B). To further validate these observations in an independent cellular model, HepG2 cells were transfected with the HBV 1.3 plasmid, either alone or in combination with the NOX2 expression plasmid. Western blot analysis revealed that expression of the HBV increased NOX2 protein abundance relative to the negative control, whereas co-transfection with the NOX2 expression plasmid further enhanced NOX2 protein expression (Fig. 4C). Densitometric quantification confirmed a significant elevation in HBc protein abundance in the HBV plus NOX2 plasmid group compared with the HBV only group (P<0.01). Moreover, HBV 1.3 transfection alone significantly increased NOX2 mRNA abundance compared with the negative control group (P<0.01, Fig. 4D). Co-transfection with the NOX2 expression plasmid resulted in a substantial additional increase in NOX2 mRNA expression compared with HBV 1.3 plasmid transfection alone (P<0.01). Furthermore, NOX2 co-expression significantly increased HBV 3.5-kb RNA abundance compared with cells transfected with the HBV 1.3 alone (P<0.01, Fig. 4E).

Overexpression of NOX2 promotes HBV
replication. (A) Representative western blot images and
corresponding densitometric quantification of NOX2 and HBc
expression in HepG2.2.15 cells transfected with a NOX2 plasmid or
NC. (B) RT-qPCR analysis of NOX2 mRNA and HBV 3.5-kb RNA expression
in HepG2.2.15 cells following NOX2 plasmid transfection. (C)
Representative western blot images and densitometric quantification
of NOX2 and HBc protein expression in HepG2 cells transfected with
empty vector (NC), the HBV 1.3 plasmid (HBV1.3), or HBV1.3 together
with the NOX2 plasmid. (D) Relative NOX2 mRNA expression in HepG2
cells transfected with NC, HBV1.3, or HBV1.3 plus the NOX2 plasmid,
as determined by RT-qPCR. (E) Relative HBV 3.5-kb RNA expression in
HepG2 cells transfected with HBV1.3 alone or co-transfected with
HBV1.3 and the NOX2 plasmid. β-actin served as the internal loading
control for western blot analysis, and protein band intensities
were quantified by densitometry and normalized to β-actin. Data are
presented as the mean ± SD of three independent experiments.
**P<0.01 compared with the corresponding control
groups or between the indicated experimental groups. NOX2, NADPH
oxidase 2; HBV, hepatitis B virus; HBc, HBV core protein; NC,
negative control; RT-qPCR, reverse transcription-quantitative
PCR.

Figure 4

Overexpression of NOX2 promotes HBV replication. (A) Representative western blot images and corresponding densitometric quantification of NOX2 and HBc expression in HepG2.2.15 cells transfected with a NOX2 plasmid or NC. (B) RT-qPCR analysis of NOX2 mRNA and HBV 3.5-kb RNA expression in HepG2.2.15 cells following NOX2 plasmid transfection. (C) Representative western blot images and densitometric quantification of NOX2 and HBc protein expression in HepG2 cells transfected with empty vector (NC), the HBV 1.3 plasmid (HBV1.3), or HBV1.3 together with the NOX2 plasmid. (D) Relative NOX2 mRNA expression in HepG2 cells transfected with NC, HBV1.3, or HBV1.3 plus the NOX2 plasmid, as determined by RT-qPCR. (E) Relative HBV 3.5-kb RNA expression in HepG2 cells transfected with HBV1.3 alone or co-transfected with HBV1.3 and the NOX2 plasmid. β-actin served as the internal loading control for western blot analysis, and protein band intensities were quantified by densitometry and normalized to β-actin. Data are presented as the mean ± SD of three independent experiments. **P<0.01 compared with the corresponding control groups or between the indicated experimental groups. NOX2, NADPH oxidase 2; HBV, hepatitis B virus; HBc, HBV core protein; NC, negative control; RT-qPCR, reverse transcription-quantitative PCR.

To further investigate the functional relationship between NOX2 expression, NOX2-associated enzymatic activity, and HBV replication-associated processes, combinatorial experiments were performed, involving siRNA-mediated NOX2 depletion, ectopic NOX2 overexpression and pharmacological treatment with apocynin. Initially, apocynin treatment did not produce a statistically significant additional reduction in NOX2 abundance compared with siNOX2 treatment alone (P>0.05). Importantly, NOX2 silencing significantly decreased HBc protein abundance, whereas combined treatment with siNOX2 and apocynin resulted in a further reduction in HBc expression (P<0.05 compared with siNOX2 alone) in both transiently HBV-expressing HepG2 cells and stably HBV-replicating HepG2.2.15 cells (Fig. S2A and C). Notably, apocynin treatment significantly attenuated the NOX2 overexpression-associated increase in HBc protein abundance (P<0.01), despite producing no significant reduction in NOX2 protein levels relative to the NOX2-overexpressing group (P>0.05) (Fig. S2B and D).

NOX2 may be a major source of ROS in cells stabling expressing HBV mRNA

It is widely accepted that HBV-mediated ROS can induce chronic infection and inflammatory condition, which leads to severe liver diseases (24). As demonstrated in Fig. 5A, patients with CHB showed significantly lower serum TAC levels than healthy individuals. To gain improved understanding of the role of oxidative stress in patients with CHB, the serum concentrations of TOA, an oxidative marker, were analyzed. In this setting, serum levels of TOA were significantly increased in patients with CHB compared with healthy individuals (Fig. 5B). At present, mounting evidence has reported that NOX2 is a kind of NADPH oxidases whose main function is producing ROS via catalyzing the transfer of electron of NADPH to molecular oxygen. Previously, it was found that NOX2 acts as a pivotal role in HBV-related complications (17). Therefore, it was explored whether or not NOX2-mediated ROS plays a role in generating oxidative stress in HBV stabling expressing cells. HepG2.2.15 cells were treated with apocynin and it was found that the curve of ROS peak integrally shifted to the left, and that the mean fluorescence intensity in apocynin treatment group was significantly lower than that in control group (Fig. 5C). These data suggested that suppressing NOX2 activity by apocynin can decrease ROS generation in HepG2.2.15 cells. In the present study, these findings were also confirmed and extended by showing that knockdown of NOX2 expression via siNOX2 could reduce the intracellular ROS levels (Fig. 5D). Furthermore, overexpression of NOX2 in HepG2.2.15 cells revealed that ROS generation was significantly increased (Fig. 5E). Over the years, mounting evidence has indicated that ROS may act as an important player in HBV replication. In the present study, it was found that both NAC and Trolox significantly decreased HBc protein abundance compared with untreated controls (P<0.01, Fig. 5F). Notably, NOX2 protein abundance remained largely unchanged following antioxidant treatment, with no statistically significant differences observed among the experimental groups (P>0.05). Furthermore, a genetically encoded fluorescent hydrogen peroxide sensor, cyto-HyPer, was employed to monitor cytosolic H2O2-associated changes in HepG2 cells expressing the HBV. HBV expression significantly increased the HyPer fluorescence excitation ratio (500/420 nm) compared with control cells (P<0.01, Fig. 5G), indicating an enhanced cytosolic H2O2-sensitive response in HBV-expressing hepatocytes. Importantly, treatment with either NAC or Trolox significantly attenuated the HBV-associated increase in the HyPer ratio. Additionally, western blot analysis demonstrated that treatment with either NAC or Trolox significantly reduced HBc abundance compared with untreated HBV1.3-expressing cells (both P<0.01, Fig. 5H). By contrast, NOX2 protein abundance did not exhibit statistically significant changes following antioxidant treatment relative to the HBV1.3 group (P>0.05). In summary, these results strongly demonstrated that high levels of NOX2 in HBV-infected cells are the main cause of excessive production of intracellular ROS, and that NOX2-mediated ROS plays a crucial role in HBV replication.

Enhanced oxidative stress in CHB and
the role of NOX2-derived ROS in HBV-replicating hepatocytes. (A and
B) Comparison of TAC (A) and TOA (B) between healthy individuals
and patients with CHB. Patients with CHB exhibited significantly
reduced TAC and elevated TOA compared with healthy controls. (C-E)
Representative flow cytometric histograms and corresponding
quantitative analysis of intracellular ROS-associated fluorescence
in HepG2.2.15 cells following pharmacological inhibition of
NOX-associated activity with apocynin (C), siRNA-mediated NOX2
knockdown (D), or ectopic overexpression of NOX2 (E). Intracellular
oxidant-sensitive fluorescence was assessed using the DCFH-DA
assay. Apocynin treatment and NOX2 silencing significantly
decreased DCF fluorescence, whereas NOX2 overexpression enhanced
intracellular ROS-associated fluorescence. (F) Representative
western blot images and corresponding densitometric quantification
of NOX2 and HBc expression in HepG2.2.15 cells treated with the
antioxidants NAC (5 mM) or Trolox (200 μM). Both antioxidant
treatments significantly reduced HBc protein abundance without
significantly altering NOX2 protein expression. (G) Quantitative
analysis of cytosolic hydrogen peroxide-sensitive fluorescence in
HepG2 cells expressing the HBV 1.3 plasmid (HBV1.3), with or
without NAC or Trolox treatment. Cytosolic
H2O2-associated changes were monitored using
the genetically encoded fluorescent biosensor cyto-HyPer and
expressed as the fluorescence excitation ratio at 500/420 nm.
HBV1.3 expression significantly increased the HyPer ratio, whereas
NAC and Trolox treatment attenuated this increase. (H)
Representative western blot images and corresponding densitometric
quantification of NOX2 and HBc protein expression in HepG2 cells
transfected with HBV1.3 and subsequently treated with NAC or
Trolox. Both antioxidants significantly suppressed HBc protein
accumulation without significantly affecting NOX2 protein abundance
relative to untreated HBV1.3-expressing cells. β-actin served as
the internal loading control for western blot analysis, and protein
band intensities were quantified by densitometry and normalized to
β-actin. Data are presented as the mean ± SD of three independent
experiments. **P<0.01. CHB, chronic hepatitis B;
NOX2, NADPH oxidase 2; ROS, reactive oxygen species; HBV, hepatitis
B virus; TAC, total antioxidant capacity; TOA, total oxidant
activity; si-, small interfering; DCFH-DA,
2',7'-dichloro-dihydro-fluorescein diacetate; HBc, HBV core
protein; NAC, N-acetylcysteine; NS, not significant; NC, negative
control.

Figure 5

Enhanced oxidative stress in CHB and the role of NOX2-derived ROS in HBV-replicating hepatocytes. (A and B) Comparison of TAC (A) and TOA (B) between healthy individuals and patients with CHB. Patients with CHB exhibited significantly reduced TAC and elevated TOA compared with healthy controls. (C-E) Representative flow cytometric histograms and corresponding quantitative analysis of intracellular ROS-associated fluorescence in HepG2.2.15 cells following pharmacological inhibition of NOX-associated activity with apocynin (C), siRNA-mediated NOX2 knockdown (D), or ectopic overexpression of NOX2 (E). Intracellular oxidant-sensitive fluorescence was assessed using the DCFH-DA assay. Apocynin treatment and NOX2 silencing significantly decreased DCF fluorescence, whereas NOX2 overexpression enhanced intracellular ROS-associated fluorescence. (F) Representative western blot images and corresponding densitometric quantification of NOX2 and HBc expression in HepG2.2.15 cells treated with the antioxidants NAC (5 mM) or Trolox (200 μM). Both antioxidant treatments significantly reduced HBc protein abundance without significantly altering NOX2 protein expression. (G) Quantitative analysis of cytosolic hydrogen peroxide-sensitive fluorescence in HepG2 cells expressing the HBV 1.3 plasmid (HBV1.3), with or without NAC or Trolox treatment. Cytosolic H2O2-associated changes were monitored using the genetically encoded fluorescent biosensor cyto-HyPer and expressed as the fluorescence excitation ratio at 500/420 nm. HBV1.3 expression significantly increased the HyPer ratio, whereas NAC and Trolox treatment attenuated this increase. (H) Representative western blot images and corresponding densitometric quantification of NOX2 and HBc protein expression in HepG2 cells transfected with HBV1.3 and subsequently treated with NAC or Trolox. Both antioxidants significantly suppressed HBc protein accumulation without significantly affecting NOX2 protein abundance relative to untreated HBV1.3-expressing cells. β-actin served as the internal loading control for western blot analysis, and protein band intensities were quantified by densitometry and normalized to β-actin. Data are presented as the mean ± SD of three independent experiments. **P<0.01. CHB, chronic hepatitis B; NOX2, NADPH oxidase 2; ROS, reactive oxygen species; HBV, hepatitis B virus; TAC, total antioxidant capacity; TOA, total oxidant activity; si-, small interfering; DCFH-DA, 2',7'-dichloro-dihydro-fluorescein diacetate; HBc, HBV core protein; NAC, N-acetylcysteine; NS, not significant; NC, negative control.

NOX2-mediated ROS may be involved in HBV replication via autophagy

Over the years, incrasing evidence has indicated that HBV can induce autophagy in host cells, which are involved in viral replication and pathogenesis (25,26). However, the precise mechanism of HBV-induced autophagy remains to be established. Firstly, HepG2 cells expressing the HBV were subjected to NOX2 silencing or treatment with the antioxidant NAC. Western blot analysis revealed that HBV expression was accompanied by a significant reduction in p62 protein abundance and a significant increase in the LC3-II/LC3-I ratio compared with control cells (Fig. 6A). These alterations are consistent with enhanced autophagy-associated activity following HBV expression. Importantly, siRNA-mediated NOX2 knockdown substantially attenuated these changes, restoring p62 abundance and reducing the LC3-II/LC3-I ratio toward control levels. Similarly, NAC treatment reversed the HBV-associated alterations in p62 and LC3 expression. Densitometric quantification demonstrated that the reduction in p62 abundance and elevation in the LC3-II/LC3-I ratio induced by HBV were statistically significant (P<0.01), whereas both parameters returned toward basal levels following NOX2 depletion or NAC treatment. These findings suggest that NOX2-associated oxidative signaling contributes to HBV-induced changes in autophagy-related protein expression. In addition, ectopic NOX2 expression further decreased p62 abundance and increased the LC3-II/LC3-I ratio compared with cells expressing HBV alone (Fig. 6B). Conversely, treatment with the antioxidant Trolox attenuated these NOX2-associated alterations. Quantitative analysis demonstrated that NOX2 overexpression significantly reduced p62 expression and increased the LC3-II/LC3-I ratio, whereas Trolox treatment partially reversed these changes. To further examine the effects of NOX2 levels on intracellular autophagy, the effects of pharmacological NOX-associated inhibition and genetic NOX2 manipulation were subsequently examined on autophagy-associated protein expression in HepG2.2.15 cells. As illustrated in Fig. 6C, treatment with apocynin significantly increased p62 protein abundance (P<0.001) while decreasing the LC3-II/LC3-I ratio (P<0.01) compared with vehicle-treated controls. Similarly, siRNA-mediated NOX2 depletion resulted in a significant elevation in p62 expression (P<0.01) and a pronounced reduction in the LC3-II/LC3-I ratio (P<0.0001; Fig. 6D). By contrast, ectopic overexpression of NOX2 significantly decreased p62 abundance (P<0.05) and increased the LC3-II/LC3-I ratio (P<0.01; Fig. 6E). These complementary loss- and gain-of-function experiments demonstrate that NOX2 expression is closely associated with the regulation of autophagy-related protein profiles in HBV-expressing hepatocytes. Furthermore, HepG2.2.15 cells were treated with rapamycin, an mTOR pathway inhibitor commonly used to stimulate autophagy, or 3-MA, an inhibitor of phosphatidylinositol 3-kinase signaling that can suppress autophagy initiation under specific experimental conditions. In the settings of the present study, rapamycin treatment increased the LC3-II/LC3-I ratio and was accompanied by enhanced HBc protein abundance, whereas 3-MA treatment reduced the LC3-II/LC3-I ratio and HBc expression (Fig. 6F). Additionally, western blot analysis demonstrated a concentration-dependent increase in HBc protein abundance following rapamycin exposure (Fig. 6G). Finally, by employing IF laser confocal, it was observed that control cells exhibited detectable cytoplasmic LC3-positive puncta, whereas siRNA-mediated NOX2 depletion markedly reduced the apparent abundance of these structures. Conversely, NOX2 overexpression was associated with increased LC3-positive punctate staining (Fig. 6H). Collectively, NOX2-mediated ROS may participate in HBV replication through autophagy.

NOX2 may be involved in HBV
replication via autophagy. (A) Representative western blot images
and corresponding densitometric quantification of p62/SQSTM1, LC3-I
and LC3-II, NOX2 and HBc in HepG2 cells transfected with the HBV
1.3 plasmid (HBV1.3), with or without NOX2-specific siRNA (siNOX2)
or NAC treatment. HBV1.3 expression decreased p62 abundance and
increased the LC3-II/LC3-I ratio, whereas NOX2 silencing or NAC
treatment attenuated these alterations. (B) Representative western
blot images and densitometric quantification of p62, LC3-I/II, NOX2
and HBc in HepG2 cells expressing HBV1.3, with or without NOX2
overexpression or Trolox treatment. Ectopic NOX2 expression further
reduced p62 abundance and increased the LC3-II/LC3-I ratio, while
Trolox attenuated these changes. (C-E) Representative western blot
images and corresponding quantitative analyses of p62 expression
and the LC3-II/LC3-I ratio in HepG2.2.15 cells following
pharmacological inhibition of NOX-associated activity with apocynin
(C), siRNA-mediated NOX2 knockdown (D), or ectopic NOX2
overexpression (E). Apocynin treatment and NOX2 depletion increased
p62 abundance and decreased the LC3-II/LC3-I ratio, whereas NOX2
overexpression produced the opposite effects. (F) Representative
western blot analysis and densitometric quantification of LC3-I/II
and HBc expression in HepG2.2.15 cells treated with rapamycin, an
mTOR pathway inhibitor commonly used to induce autophagy, or 3-MA,
an inhibitor of autophagy initiation under the experimental
conditions employed. Rapamycin increased the LC3-II/LC3-I ratio and
HBc protein abundance, whereas 3-MA reduced both parameters. (G)
Representative western blot images and densitometric quantification
of HBc expression in HepG2.2.15 cells treated with increasing
concentrations of rapamycin (20, 40, 60, and 100 nM). Rapamycin
enhanced HBc protein abundance in a concentration-dependent manner.
(H) Representative immunofluorescence images showing LC3
distribution in HepG2.2.15 cells under mock-control conditions,
following siNOX2 transfection, or following NOX2 plasmid-mediated
overexpression. LC3-positive structures were visualized in red, and
nuclei were counterstained with DAPI (blue). NOX2 silencing reduced
the apparent abundance of LC3-positive puncta, whereas NOX2
overexpression enhanced punctate LC3 staining. β-actin served as
the internal loading control for western blot analysis. Protein
band intensities were quantified by densitometry and normalized to
β-actin, while LC3 processing was evaluated using the LC3-II/LC3-I
ratio. Data are presented as the mean ± SD of three independent
experiments. Statistical significance is indicated relative to the
corresponding control groups or between the indicated experimental
groups: *P<0.05, **P<0.01,
***P<0.001 and ****P<0.0001. NOX2,
NADPH oxidase 2; HBV, hepatitis B virus; LC3,
microtubule-associated protein 1 light chain 3; HBc, HBV core
protein; si-, small interfering; NAC, N-acetylcysteine; 3-MA,
3-methyladenine; NS, not significant.

Figure 6

NOX2 may be involved in HBV replication via autophagy. (A) Representative western blot images and corresponding densitometric quantification of p62/SQSTM1, LC3-I and LC3-II, NOX2 and HBc in HepG2 cells transfected with the HBV 1.3 plasmid (HBV1.3), with or without NOX2-specific siRNA (siNOX2) or NAC treatment. HBV1.3 expression decreased p62 abundance and increased the LC3-II/LC3-I ratio, whereas NOX2 silencing or NAC treatment attenuated these alterations. (B) Representative western blot images and densitometric quantification of p62, LC3-I/II, NOX2 and HBc in HepG2 cells expressing HBV1.3, with or without NOX2 overexpression or Trolox treatment. Ectopic NOX2 expression further reduced p62 abundance and increased the LC3-II/LC3-I ratio, while Trolox attenuated these changes. (C-E) Representative western blot images and corresponding quantitative analyses of p62 expression and the LC3-II/LC3-I ratio in HepG2.2.15 cells following pharmacological inhibition of NOX-associated activity with apocynin (C), siRNA-mediated NOX2 knockdown (D), or ectopic NOX2 overexpression (E). Apocynin treatment and NOX2 depletion increased p62 abundance and decreased the LC3-II/LC3-I ratio, whereas NOX2 overexpression produced the opposite effects. (F) Representative western blot analysis and densitometric quantification of LC3-I/II and HBc expression in HepG2.2.15 cells treated with rapamycin, an mTOR pathway inhibitor commonly used to induce autophagy, or 3-MA, an inhibitor of autophagy initiation under the experimental conditions employed. Rapamycin increased the LC3-II/LC3-I ratio and HBc protein abundance, whereas 3-MA reduced both parameters. (G) Representative western blot images and densitometric quantification of HBc expression in HepG2.2.15 cells treated with increasing concentrations of rapamycin (20, 40, 60, and 100 nM). Rapamycin enhanced HBc protein abundance in a concentration-dependent manner. (H) Representative immunofluorescence images showing LC3 distribution in HepG2.2.15 cells under mock-control conditions, following siNOX2 transfection, or following NOX2 plasmid-mediated overexpression. LC3-positive structures were visualized in red, and nuclei were counterstained with DAPI (blue). NOX2 silencing reduced the apparent abundance of LC3-positive puncta, whereas NOX2 overexpression enhanced punctate LC3 staining. β-actin served as the internal loading control for western blot analysis. Protein band intensities were quantified by densitometry and normalized to β-actin, while LC3 processing was evaluated using the LC3-II/LC3-I ratio. Data are presented as the mean ± SD of three independent experiments. Statistical significance is indicated relative to the corresponding control groups or between the indicated experimental groups: *P<0.05, **P<0.01, ***P<0.001 and ****P<0.0001. NOX2, NADPH oxidase 2; HBV, hepatitis B virus; LC3, microtubule-associated protein 1 light chain 3; HBc, HBV core protein; si-, small interfering; NAC, N-acetylcysteine; 3-MA, 3-methyladenine; NS, not significant.

Discussion

HBV establishes persistent infection through complex interactions with host cellular signaling networks, particularly those governing oxidative homeostasis, intracellular metabolism and autophagy. Increasing evidence indicates that HBV can manipulate these processes to create a cellular environment favorable for viral replication and persistence. However, the molecular mechanisms connecting HBV-associated oxidative stress with autophagy regulation remain incompletely understood. In the present study, NOX2 was identified as a host regulatory factor associated with HBV replication-related processes. The present findings support a mechanistic model in which HBV-associated NOX2 upregulation contributes to intracellular ROS accumulation and autophagy-associated alterations, thereby establishing conditions that favor HBV gene expression and replication.

Accumulating evidence indicates that HBV exploits multiple host-signaling pathways to facilitate viral replication. Previous studies have demonstrated that HBV and its regulatory protein HBx modulate EGFR- and PI3K/Akt-associated signaling, highlighting the importance of host signaling networks in HBV pathogenesis (27-29). In this context, the present findings identify NOX2-associated ROS production and autophagy regulation as an additional host-signaling mechanism that may contribute to HBV replication. These observations further suggest that HBV replication is influenced by interconnected cellular signaling and metabolic processes, although potential crosstalk between NOX2/ROS/autophagy and EGFR/PI3K/Akt signaling remains to be elucidated. An important finding of the present study is the positive association between HBV expression and NOX2 abundance. It was demonstrated that NOX2 mRNA and protein levels were significantly elevated in both transiently HBV-expressing HepG2 cells and stably HBV-replicating HepG2.2.15 cells. Consistent with these observations, circulating soluble NOX2-derived peptide (sNOX2-dp) concentrations were significantly increased in patients with CHB and positively correlated with serum HBV DNA levels (r=0.4674, P<0.0001). Furthermore, pharmacological inhibition and siRNA-mediated NOX2 silencing significantly reduced HBc abundance and viral 3.5-kb RNA expression, whereas ectopic NOX2 overexpression enhanced these parameters. These complementary observations suggest that NOX2 contributes to a host-cell environment favorable for HBV replication-associated processes. Nevertheless, the clinical association does not establish causality, and the viral RNA and protein measurements should not be considered equivalent to direct quantification of infectious viral progeny.

The relationship between HBV and NOX2 may be contextualized within the established functions of hepatitis B virus X protein (HBx), a multifunctional viral regulatory protein involved in host signaling, mitochondrial homeostasis, and cellular stress responses. Previous investigations have demonstrated that HBx can alter mitochondrial function, intracellular calcium signaling, and ROS generation, thereby influencing redox-sensitive signaling pathways implicated in HBV-associated pathogenesis (30). Mitochondrial ROS have also been implicated in the activation of inflammatory and survival-associated signaling networks, including the IL-6/STAT3 pathway. These findings suggest that oxidative signaling constitutes an important component of HBV-mediated host-cell reprogramming. In this context, the observation of increased NOX2 expression raises the possibility that NADPH oxidase-dependent ROS production represents an additional mechanism contributing to HBV-associated oxidative remodeling. However, whether HBx directly regulates NOX2 transcription, enzymatic activation, or intracellular localization remains unknown. Accordingly, a direct HBx-NOX2 signaling relationship should be regarded as a hypothesis requiring experimental validation rather than an established conclusion.

ROS function not only as mediators of oxidative injury but also as intracellular signaling molecules capable of regulating protein phosphorylation, transcriptional activity and metabolic adaptation. Their biological effects depend on intracellular concentration, subcellular localization, and duration of exposure. In the present study, NOX2 knockdown significantly attenuated intracellular ROS accumulation, whereas NOX2 overexpression enhanced ROS-associated fluorescence signals. Furthermore, treatment with the antioxidants NAC and Trolox reduced HBc protein abundance without significantly altering NOX2 expression. Measurements using the genetically encoded cytosolic HyPer sensor additionally demonstrated enhanced H2O2-sensitive responses in HBV-expressing cells, which were attenuated by antioxidant treatment. Together, these observations support the involvement of NOX2-associated oxidative signaling in HBV gene expression. Nevertheless, mitochondrial metabolism, endoplasmic reticulum stress and other oxidant-generating systems may also contribute to the intracellular ROS pool. Therefore, NOX2 should be considered a functionally relevant source of HBV-associated oxidative signaling rather than the exclusive determinant of cellular ROS production.

Autophagy represents an important downstream cellular process potentially influenced by HBV-associated oxidative stress. Previous studies have established that HBV can exploit host autophagy machinery to facilitate viral DNA replication. Tang et al (31) demonstrated that HBx enhances starvation-induced autophagy by upregulating Beclin 1 expression. Subsequently, Sir et al (32) reported that HBV activates early autophagic processes through HBx-mediated stimulation of class III phosphatidylinositol 3-kinase, thereby facilitating viral DNA replication without a corresponding enhancement of autophagic protein degradation (32). Additional investigations identified death-associated protein kinase as a regulator of HBx-induced autophagy through a Beclin 1-associated mechanism (33). Importantly, Liu et al (34) demonstrated that HBx can impair lysosomal acidification and autophagic degradation despite promoting autophagosome formation. These findings highlight the complexity of HBV-autophagy interactions and indicate that HBV may selectively manipulate different stages of the autophagic pathway rather than uniformly enhance autophagic flux.

The experimental findings extend this framework by implicating NOX2-associated oxidative signaling in the regulation of autophagy-related processes during HBV expression. HBV-expressing cells exhibited increased LC3-II/LC3-I ratios and decreased p62 abundance, whereas NOX2 silencing or NAC treatment attenuated these alterations. Conversely, NOX2 overexpression further increased LC3 lipidation-associated changes and reduced p62 expression, while Trolox partially reversed these effects. Consistent with these observations, IF analysis revealed corresponding alterations in LC3-positive punctate structures following NOX2 manipulation. Moreover, rapamycin treatment increased HBc abundance, whereas 3-MA decreased HBc expression under the experimental conditions examined. Collectively, these results suggest a functional association among NOX2-dependent redox signaling, autophagy-associated cellular remodeling, and HBV protein accumulation. However, LC3 conversion, p62 abundance and LC3 puncta do not independently establish dynamic autophagic flux. Thus, the findings of the present study support NOX2-dependent modulation of autophagy-associated processes but do not definitively demonstrate enhanced autophagic degradation.

Mechanistically, NOX2-associated ROS may influence autophagy through redox-sensitive signaling pathways regulating autophagosome biogenesis and cellular stress adaptation. Potential intermediates include AMPK-mTOR signaling, MAPK cascades and regulatory proteins involved in autophagy initiation. These mechanisms may provide a molecular connection between HBV-induced oxidative remodeling and the autophagy-related changes observed in the present study. Nevertheless, their direct involvement was not examined experimentally, and the precise molecular intermediates linking NOX2 activity to autophagy regulation remain unresolved. Further investigations combining pathway-specific genetic manipulation, phosphorylation analyses, and dynamic autophagic flux measurements will be required to establish the directionality and molecular specificity of this signaling relationship.

However, several limitations should be acknowledged. First, the upstream mechanisms through which HBV enhances NOX2 expression remain unclear. It is unknown whether this response is mediated directly by specific viral proteins or indirectly through host inflammatory, metabolic, or oxidative signaling pathways. Second, although the results of the present study implicate ROS-associated signaling in the regulation of autophagy-related markers, the specific molecular intermediates have not been identified. Third, the assessment of autophagy was based primarily on LC3 conversion, p62 abundance and LC3-positive punctate staining. These measurements provide evidence of changes in autophagy-associated processes but cannot independently distinguish enhanced autophagic flux from altered autophagosome turnover. Future studies incorporating lysosomal blockade, tandem fluorescent LC3 reporters and genetic manipulation of ATG5, ATG7, or other essential autophagy-related proteins would provide stronger evidence regarding the functional contribution of autophagy.

Collectively, the current findings support a working model in which HBV-associated NOX2 upregulation contributes to intracellular oxidative signaling and autophagy-related alterations that favor HBV gene expression and replication-associated processes. Although additional studies are required to establish the complete molecular signaling cascade and its physiological relevance, the present findings identify NOX2 as a potentially important host regulatory factor and provide a foundation for investigating redox-dependent host-directed strategies against HBV infection.

Supplementary Data

Availability of data and materials

The data generated in the present study may be requested from the corresponding author.

Authors' contributions

XYS and BW contributed to the conception and design of the study. LLD, JY, LC and YZ coordinated the investigation of sample analysis. XYS, LLD and JY conducted experiments. XYS, LBC, MMR, GWH and BW performed data analysis. XYS and BW confirm the authenticity of all the raw data. XYS and BW drafted the manuscript. All authors read and approved the final version of the manuscript.

Ethics approval and consent to participate

The present study was approved by the ethics committee of the Second Affiliated Hospital of Chongqing Medical University and performed in accordance with the principles of the Declaration of Helsinki (approval no. 2025534; Chongqing, China). Written informed consent was provided by all participants.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Abbreviations:

NOX2

NADPH oxidase 2

HBV

hepatitis B virus

CHB

chronic hepatitis B

HCC

hepatocellular carcinoma

ROS

reactive oxygen species

HBc

HBV core protein

LC3

microtubule-associated protein-Light-chain 3

NC

negative control

Acknowledgements

The authors would like to thank Dr Pu Li (Chongqing University Jiangjin Hospital, Chongqing, China) for his insightful comments on the experimental design.

Funding

The present study was supported by grants from National Natural Science Foundation of China (grant no. 81501806), the Natural Science Foundation of Chongqing Municipality (grant nos. cstc2018jcyjAX0745 and CSTB2023NSCQ-MSX0215), the Open Project of Chongqing Key Laboratory of Highly Pathogenic Microbes (grant no. 2025ZDSYS003), the Nan'an Science and Health Joint Medical Research Project Key Project (grant no. 2027-02), the China Postdoctoral Science Foundation (grant nos. 2024MD754026 and 2025T180626) and the Kuanren Talents Program of the Second Affiliated Hospital of Chongqing Medical University (grant no. 202417-45).

References

1 

Jung M and Pape GR: Immunology of hepatitis B infection. Lancet Infect Dis. 2:43, –50. 2002. View Article : Google Scholar : PubMed/NCBI

2 

Hiebert-Suwondo L, Manning J, Tohme RA, Buti M, Kondili LA, Spearman CW, Prabdial-Sing N, Turnier V, Lazarus JV, Waked I, et al: A 2024 global report on national policy, programmes, and progress towards hepatitis B elimination: Findings from 33 hepatitis elimination profiles. Lancet Gastroenterol Hepatol. 10:671, –684. 2025. View Article : Google Scholar : PubMed/NCBI

3 

Wong GLH and Lemoine M: The 2024 updated WHO guidelines for the prevention and management of chronic hepatitis B: Main changes and potential implications for the next major liver society clinical practice guidelines. J Hepatol. 82:918, –925. 2025. View Article : Google Scholar

4 

Ye B, Liu X, Li X, Kong H, Tian L and Chen Y: T-cell exhaustion in chronic hepatitis B infection: Current knowledge and clinical significance. Cell Death Dis. 6:e1694, 2015. View Article : Google Scholar : PubMed/NCBI

5 

Lumley SF, Mokaya J, Maponga TG, Kramvis A, Dusheiko G, Irving W, Delphin M, Said Mohammed K, Downs LO, Waddilove E, et al: Hepatitis B virus resistance to nucleos(t)ide analogue therapy: WHO consultation on questions, challenges, and a roadmap for the field. Lancet Microbe. 6:101076, 2025. View Article : Google Scholar : PubMed/NCBI

6 

Yuan K, Lei Y, Chen HN, Chen Y, Zhang T, Li K, Xie N, Wang K, Feng X, Pu Q, et al: HBV-induced ROS accumulation promotes hepatocarcinogenesis through Snail-mediated epigenetic silencing of SOCS3. Cell Death Differ. 23:616, –627. 2016. View Article : Google Scholar : PubMed/NCBI

7 

Yu X, Lan P, Hou X, Han Q, Lu N, Li T, Jiao C, Zhang J, Zhang C and Tian Z: HBV inhibits LPS-induced NLRP3 inflammasome activation and IL-1β production via suppressing the NF-κB pathway and ROS production. J Hepatol. 66:693, –702. 2017. View Article : Google Scholar

8 

Pignatelli P, Carnevale R, Cangemi R, Loffredo L, Sanguigni V, Stefanutti C, Basili S and Violi F: Atorvastatin inhibits gp91phox circulating levels in patients with hypercholesterolemia. Arterioscler Thromb Vasc Biol. 30:360, –367. 2010. View Article : Google Scholar

9 

Lambeth JD, Kawahara T and Diebold B: Regulation of Nox and Duox enzymatic activity and expression. Free Radic Biol Med. 43:319, –331. 2007. View Article : Google Scholar : PubMed/NCBI

10 

Bedard K and Krause KH: The NOX family of ROS-generating NADPH oxidases: Physiology and pathophysiology. Physiol Rev. 87:245, –313. 2007. View Article : Google Scholar : PubMed/NCBI

11 

Panday A, Sahoo MK, Osorio D and Batra S: NADPH oxidases: An overview from structure to innate immunity-associated pathologies. Cell Mol Immunol. 12:5, –23. 2015. View Article : Google Scholar :

12 

Segal BH, Veys P, Malech H and Cowan MJ: Chronic granulomatous disease: Lessons from a rare disorder. Biol Blood Marrow Transplant. 17(1 Suppl): S123, –S131. 2011. View Article : Google Scholar : PubMed/NCBI

13 

Kuhns DB, Alvord WG, Heller T, Feld JJ, Pike KM, Marciano BE, Uzel G, DeRavin SS, Priel DAL, Soule BP, et al: Residual NADPH oxidase and survival in chronic granulomatous disease. N Engl J Med. 363:2600, –2610. 2010. View Article : Google Scholar : PubMed/NCBI

14 

Yuan Z, Liu M, Zhang L, Jia L, Hao S, Su D, Tang L, Wang C, Wang M and Wen Z: Notch1 hyperactivity drives ubiquitination of NOX2 and dysfunction of CD8+ regulatory T cells in patients with systemic lupus erythematosus. Rheumatology (Oxford). 64:1500, –1512. 2025. View Article : Google Scholar

15 

Youn GS, Cho H, Kim D, Choi SY and Park J: Crosstalk between HDAC6 and Nox2-based NADPH oxidase mediates HIV-1 Tat-induced pro-inflammatory responses in astrocytes. Redox Biol. 12:978, –986. 2017. View Article : Google Scholar : PubMed/NCBI

16 

Pastori D, Esposito A, Carnevale R, Bartimoccia S, Novo M, Fantauzzi A, Di Campli F, Pignatelli P, Violi F and Mezzaroma I: HIV-1 induces in vivo platelet activation by enhancing platelet NOX2 activity. J Infect. 70:651, –658. 2015. View Article : Google Scholar : PubMed/NCBI

17 

Xiong Y, Ye Y, Li P, Xiong Y, Mao J, Huang Y, Chen W and Wang B: Serum NOX2 as a new biomarker candidate for HBV-related disorders. Am J Transl Res. 10:2350, –2361. 2018.PubMed/NCBI

18 

Hou J, Wang G, Wang F, Cheng J, Ren H, Zhuang H, Sun J, Li L, Li J, Meng Q, et al: Guideline of prevention and treatment for chronic hepatitis B (2015 update). J Clin Transl Hepatol. 5:297, –318. 2017. View Article : Google Scholar : PubMed/NCBI

19 

Yang J, Xiong Y, Zhou L, Huang Y, Chen W and Wang B: Soluble E-cadherin is associated with oxidative stress in patients with chronic HBV infection. J Med Virol. 92:34, –44. 2020. View Article : Google Scholar

20 

Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402, –408. 2001. View Article : Google Scholar

21 

Deng L, Chen L, Ren M, Liang Y, He G, Tang X, Yang T, Xu J, Long T, Zhao Q and Wang B: Lipoprotein (a) fuels EV71 replication by activating p38 MAPK-autophagy axis. Front Immunol. 17:1865808, 2026. View Article : Google Scholar : PubMed/NCBI

22 

Stolk J, Hiltermann TJ, Dijkman JH and Verhoeven AJ: Characteristics of the inhibition of NADPH oxidase activation in neutrophils by apocynin, a methoxy-substituted catechol. Am J Respir Cell Mol Biol. 11:95, –102. 1994. View Article : Google Scholar : PubMed/NCBI

23 

Heumüller S, Wind S, Barbosa-Sicard E, Schmidt HHHW, Busse R, Schröder K and Brandes RP: Apocynin is not an inhibitor of vascular NADPH oxidases but an antioxidant. Hypertension. 51:211, –217. 2008. View Article : Google Scholar

24 

Kim S, Park J, Han J and Jang KL: Hepatitis B virus X protein induces reactive oxygen species generation via activation of p53 in human hepatoma cells. Biomolecules. 14:1201, 2024. View Article : Google Scholar : PubMed/NCBI

25 

Mei L, Sun H, Yan Y, Ji H, Su Q, Chang L and Wang L: mTOR signaling: Roles in hepatitis B virus infection and hepatocellular carcinoma. Int J Biol Sci. 20:4178, –4189. 2024. View Article : Google Scholar : PubMed/NCBI

26 

Zhang H, Liang T, Duan W, Liu F, Li L, Liu Q, Li J, Zong Q, Jin L, Wang Q and Zhou Q: STING modulates HBV-related acute-on-chronic liver failure by mediating autophagy and macrophage polarization. Immunobiology. 230:152860, 2025. View Article : Google Scholar

27 

Lin Y, Liu Y, Xu D, Guo F, Zhang W, Zhang Y and Bai G: HBxAg promotes HBV replication and EGFR activation in human placental trophoblasts. Exp Ther Med. 22:1211, 2021. View Article : Google Scholar : PubMed/NCBI

28 

Wang W, Shi Y, Bai G, Tang Y, Yuan Y, Zhang T and Li C: HBxAg suppresses apoptosis of human placental trophoblastic cell lines via activation of the PI3K/Akt pathway. Cell Biol Int. 40:708, –715. 2016. View Article : Google Scholar : PubMed/NCBI

29 

Wang W, Bai G, Zhang Y, Zhang T, Li C, Yuan Y, Liu S and Wang C: HBxAg suppresses cell apoptosis and promotes the secretion of placental hormones in human placental trophoblasts via activation of the EGFR/Akt pathway. Cell Biol Int. 42:237, –247. 2018. View Article : Google Scholar

30 

Li Y and Ou JJ: Regulation of mitochondrial metabolism by hepatitis B virus. Viruses. 15:2359, 2023. View Article : Google Scholar : PubMed/NCBI

31 

Tang H, Da L, Mao Y, Li Y, Li D, Xu Z, Li F, Wang Y, Tiollais P, Li T and Zhao M: Hepatitis B virus X protein sensitizes cells to starvation-induced autophagy via up-regulation of beclin 1 expression. Hepatology. 49:60, –71. 2009. View Article : Google Scholar

32 

Sir D, Tian Y, Chen WL, Ann DK, Yen TSB and Ou JHJ: The early autophagic pathway is activated by hepatitis B virus and required for viral DNA replication. Proc Natl Acad Sci USA. 107:4383, –4388. 2010. View Article : Google Scholar : PubMed/NCBI

33 

Zhang HT, Chen GG, Hu BG, Zhang ZY, Yun JP, He ML and Lai PBS: Hepatitis B virus x protein induces autophagy via activating death-associated protein kinase. J Viral Hepat. 21:642, –649. 2014. View Article : Google Scholar

34 

Liu B, Fang M, Hu Y, Huang B, Li N, Chang C, Huang R, Xu X, Yang Z, Chen Z and Liu W: Hepatitis B virus X protein inhibits autophagic degradation by impairing lysosomal maturation. Autophagy. 10:416, –430. 2014. View Article : Google Scholar : PubMed/NCBI

Related Articles

  • Abstract
  • View
  • Download
  • Twitter
Copy and paste a formatted citation
Spandidos Publications style
Sun X, Deng L, Yang J, Chen L, Ren M, He G, Zhang Y, Cheng L and Wang B: A novel role of NOX2 in enhancing HBV replication through ROS‑mediated autophagy activation. Int J Mol Med 59: 7, 2027.
APA
Sun, X., Deng, L., Yang, J., Chen, L., Ren, M., He, G. ... Wang, B. (2027). A novel role of NOX2 in enhancing HBV replication through ROS‑mediated autophagy activation. International Journal of Molecular Medicine, 59, 7. https://doi.org/10.3892/ijmm.2026.6054
MLA
Sun, X., Deng, L., Yang, J., Chen, L., Ren, M., He, G., Zhang, Y., Cheng, L., Wang, B."A novel role of NOX2 in enhancing HBV replication through ROS‑mediated autophagy activation". International Journal of Molecular Medicine 59.1 (2027): 7.
Chicago
Sun, X., Deng, L., Yang, J., Chen, L., Ren, M., He, G., Zhang, Y., Cheng, L., Wang, B."A novel role of NOX2 in enhancing HBV replication through ROS‑mediated autophagy activation". International Journal of Molecular Medicine 59, no. 1 (2027): 7. https://doi.org/10.3892/ijmm.2026.6054
Copy and paste a formatted citation
x
Spandidos Publications style
Sun X, Deng L, Yang J, Chen L, Ren M, He G, Zhang Y, Cheng L and Wang B: A novel role of NOX2 in enhancing HBV replication through ROS‑mediated autophagy activation. Int J Mol Med 59: 7, 2027.
APA
Sun, X., Deng, L., Yang, J., Chen, L., Ren, M., He, G. ... Wang, B. (2027). A novel role of NOX2 in enhancing HBV replication through ROS‑mediated autophagy activation. International Journal of Molecular Medicine, 59, 7. https://doi.org/10.3892/ijmm.2026.6054
MLA
Sun, X., Deng, L., Yang, J., Chen, L., Ren, M., He, G., Zhang, Y., Cheng, L., Wang, B."A novel role of NOX2 in enhancing HBV replication through ROS‑mediated autophagy activation". International Journal of Molecular Medicine 59.1 (2027): 7.
Chicago
Sun, X., Deng, L., Yang, J., Chen, L., Ren, M., He, G., Zhang, Y., Cheng, L., Wang, B."A novel role of NOX2 in enhancing HBV replication through ROS‑mediated autophagy activation". International Journal of Molecular Medicine 59, no. 1 (2027): 7. https://doi.org/10.3892/ijmm.2026.6054
Follow us
  • Twitter
  • LinkedIn
  • Facebook
About
  • Spandidos Publications
  • Careers
  • Cookie Policy
  • Privacy Policy
How can we help?
  • Help
  • Live Chat
  • Contact
  • Email to our Support Team